WI Harper Group was recognized as “China’s Top 100 Venture Capital Funds” in 2019 by the China-FOF Alliance

WI Harper Group | December 8, 2019

On December 8th, the 2019 Annual China FOF Conference was held in Beijing, with support from China Venture Capital Co., the China FOF Alliance, and the China FOF Research Institute.

At the end of the conference, the China FOF Alliance held an award ceremony where they selected WI Harper Group as one of China’s Top 100 Venture Capital Funds.

China’s capital markets are going through a period of constructive reforms. On one end, trade frictions between China and the United States have intensified, leading to an uncertain global economic landscape.  On the other hand, China’s financial system continues to evolve and become more competitive relative to developed markets.  For instance, China has diversified its stock exchanges through the newly launched Sci-Tech Innovation Board (STAR Market) and the National Equities Exchange and Quotations (NEEQ).  In addition, the China Securities Regulatory Commission announced the timeline to removing limits to foreign ownership in the financial sector in October.  

Against this backdrop, key players in China’s private equity fund industry are actively expanding the market and restructuring business layouts; the industry is constantly reshaping.

Opportunities and challenges coexist; hard work and achievements coexist. The China FOF Alliance held the 2019 Annual China FOF Conference in recognition of the industry leaders and to encourage practitioners to collaborate in order to promote development of China’s private equity industry.

Based on a comprehensive evaluation and scoring of various indicators, the China FOF Alliance Committee identified China’s Top 100 Venture Capital Funds and selected WI Harper Group as one of the award recipients.

Founded in 1993, WI Harper is a pioneering cross-border venture capital firm investing in early to growth stage companies across the US, Greater China, and Asia Pacific. We have invested in more than 400 companies that significantly advance – or even reinvent the wheel – the fields of healthcare, biotech, artificial intelligence, robotics, fintech, sustainability, and new media.  With over three decades of hard-earned experience, we provide our portfolio companies and entrepreneur partners with unmatched expertise in rethinking and redefining winning strategies for China and Asia, as well as access to our deep network of trusted local and global relations as they seek to grow and expand across markets.  This award is a strong affirmation of WI Harper Group’s investment strategy and social influence.

Translated from: https://mp.weixin.qq.com/s/tJb1ZrxPJ33xIL2n8fUpLQ

WI Harper Group was recognized as “China’s Top 100 Venture Capital Funds” in 2019 by the China-FOF Alliance

Resvent Medical is a Shenzhen, China-based medical device and solution company focused on medical respiration & ventilation field, with its core management team having spun out of Mindray’s hospitals respiratory division, with over a decade of experience in homecare devices, clinical respiratory healthcare, intelligent information system, related consumable & accessories and value added services, and capable of building a globally competitive respiratory player – i.e. the RESMED of China.